Search research articles
Contact Us
Filters
Showing results (301-310 of 408) with videos related to
Page
of 41
Sort By:
Seizure
|
February 9, 2020
Predicting outcome of epilepsy surgery in clinical practice: Prediction models vs. clinical acumen
Anne Katharina Fassin, Susanne Knake, Adam Strzelczyk, et al.
Journal for Immunotherapy of Cancer
|
March 25, 2021
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
Angelika M Starzer, Anna S Berghoff, Rainer Hamacher, et al.
Clinical Sarcoma Research
|
March 15, 2019
Genomic aberrations in cell cycle genes predict progression of <i>KIT</i>-mutant gastrointestinal stromal tumors (GISTs)
Michael C Heinrich, Janice Patterson, Carol Beadling, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Patrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2023
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome
Rainer Hamacher, Xiaofei Liu, Markus K Schuler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Viktor Grünwald, Annika Karch, Markus Schuler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Wolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.
The Oncologist
|
December 8, 2020
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
James H Lewis, Hans Gelderblom, Michiel van de Sande, et al.
Brain Communications
|
January 11, 2024
Differential microRNA editing may drive target pathway switching in human temporal lobe epilepsy
Kelvin E How Lau, Ngoc T Nguyen, Jaideep C Kesavan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2021
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Sebastian Bauer, Michael C Heinrich, Suzanne George, et al.
Page
of 41
Search research articles
Search
Showing results (301-310 of 408) with videos related to
Sort By:
Page
of 41
Seizure
|
February 9, 2020
Predicting outcome of epilepsy surgery in clinical practice: Prediction models vs. clinical acumen
Anne Katharina Fassin, Susanne Knake, Adam Strzelczyk, et al.
Journal for Immunotherapy of Cancer
|
March 25, 2021
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
Angelika M Starzer, Anna S Berghoff, Rainer Hamacher, et al.
Clinical Sarcoma Research
|
March 15, 2019
Genomic aberrations in cell cycle genes predict progression of <i>KIT</i>-mutant gastrointestinal stromal tumors (GISTs)
Michael C Heinrich, Janice Patterson, Carol Beadling, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Patrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2023
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome
Rainer Hamacher, Xiaofei Liu, Markus K Schuler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Viktor Grünwald, Annika Karch, Markus Schuler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Wolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.
The Oncologist
|
December 8, 2020
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
James H Lewis, Hans Gelderblom, Michiel van de Sande, et al.
Brain Communications
|
January 11, 2024
Differential microRNA editing may drive target pathway switching in human temporal lobe epilepsy
Kelvin E How Lau, Ngoc T Nguyen, Jaideep C Kesavan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2021
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Sebastian Bauer, Michael C Heinrich, Suzanne George, et al.
Page
of 41